Filter Results
Low-Dose Chemo Regimen Effective in Older Patients With Gastroesophageal Cancer
The phase III GO2 randomized trial of 514 older and frail people in the U.K. with advanced gastroesophageal cancer found that the lowest tested dose of oxaliplatin and capecitabine was comparable to the highest dose in terms of delaying disease progression and minimizing side effects.
Entrectinib Shows Promise in Pediatric Patients With Gene Fusions
In a phase I/IB study of 29 patients, ages 4.9 months to 20 years, with rare central nervous system (CNS) tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients.
Pediatric MATCH Trial Finds More Frequent Targetable Genetic Alterations Than Predicted
At the launch of the NCI-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) trial in 2017, it was estimated that tumor sequencing in children, adolescents, and young adults with treatment-refractory cancers would identify genetic alterations that matched an investigational targeted therapy in 10 percent of study participants.
Lenalidomide Limits Progression of Smoldering Myeloma
Single-agent lenalidomide can reduce the risk of smoldering myeloma progressing to overt multiple myeloma in high-risk patients.
Socioeconomic Factors Predict Long-Term Survival in Multiple Myeloma
Multiple socioeconomic factors, including private insurance, living in a regionally higher-income area, and receiving treatment in certain practice settings, leads to longer survival for multiple myeloma patients.
Race & Geographic Location Create Disparities in Multiple Myeloma
Survival rates for multiple myeloma have improved considerably in recent decades thanks to the advent of novel drugs, stem cell transplantation, and management strategies, but this survival gain is not consistent among all patients.
Insights Into Managing Elderly Patients With Multiple Myeloma
An educational session titled “Geriatric Assessment in the Management of Multiple Myeloma” at 2019 ASCO Annual Meeting focused on insights into caring for this growing population of patients.
Iberdomide in Combo With Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
The first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase I/II CC-220-MM-001 study were released during an oral presentation at the 2019 ASCO Annual Meeting.
Impact of Medicaid Expansion on Timely Cancer Treatment
Previous racial disparities in timely cancer treatment between African-American and white patients practically disappeared in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records of over 30,000 patients.